# Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Source: https://onco.cc/trials/nct07249905/  
OnCo record `nct07249905` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MDX2003 in non-Hodgkin lymphoma, waldenström macroglobulinaemia, diffuse large B-cell lymphoma and follicular lymphoma, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.

## Summary

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma is a phase 1/2 interventional study registered as NCT07249905 by ModeX Therapeutics, An OPKO Health Company, with 180 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-01. Interventions recorded: MDX2003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07249905
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies
- Sponsor: ModeX Therapeutics, An OPKO Health Company
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07249905: https://clinicaltrials.gov/study/NCT07249905

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)

---
JSON: https://onco.cc/api/v1/entities/nct07249905.json